Biosimilars and the patent law

Świerczyński, Marek; Więckowski, Zbigniew

| | SLO | ENG | Piškotki in zasebnost

Večja pisava | Manjša pisava

Prva stran > Izpis gradiva

Izpis gradiva

Naslov:	Biosimilars and the patent law
Avtorji:	ID Świerczyński, Marek (Avtor) ID Więckowski, Zbigniew (Avtor)
Datoteke:	https://journals.um.si/index.php/medicine/article/view/404 Opis: Prost dostop
Jezik:	Angleški jezik
Vrsta gradiva:	Neznano
Tipologija:	1.01 - Izvirni znanstveni članek
Organizacija:	PF - Pravna fakulteta
Opis:	Biopharmaceuticals are one of the most important recent medical innovations which revolutionised many areas of medicine. Dynamic development of the market for biopharmaceuticals in recent years is related to the expiration of the IP exclusive rights on original innovative biological medicinal products. This has resulted in introduction to the market of biosimilars. One of the greatest challenges concerning the emergence of biosimilars is modifying the law to ensure balance between the market development of biosimilars and access of patients to biological therapy. The development of biopharmaceutical inventions works hand in hand with the patent system. It should be underlined that IP rights in the biopharmaceutical sector are crucial for promoting innovation due to the very long time of product development. It is exactly the area in which patents make sense to fill the gap between innovation and the risk of imitation. However, the existing patent system is too expensive and slow for biotechnology development. It should be further adapted to the needs of biopharmaceuticals.
Ključne besede:	biopharmaceuticals, biologic medicinal product, IP exclusive rights, innovation, intellectual property
Leto izida:	2019
Št. strani:	str. 21-38
Številčenje:	Vol. 12, iss. 2
PID:	20.500.12556/DKUM-78496
UDK:	347.78
COBISS.SI-ID:	43517443
DOI:	10.18690/mls.12.2.21-38.2019
ISSN pri članku:	2463-7955
NUK URN:	URN:SI:UM:DK:USZXJYAA
Datum objave v DKUM:	15.01.2021
Število ogledov:	1099
Število prenosov:	71
Metapodatki:
Področja:	Ostalo
:	Kopiraj citat